Fatty Liver Alliance Founder Mike Betel joins Roger Green to consider how patient incentives to participate in MASH clinical trials might need to change now that prescribers have an approved drug for treating MASH patients.
MASLD patient advocates consider new needs and opportunities for other stakeholders after the Rezdiffra approval and launch.
Last Thursday, March 14, Rezdiffra (resmetirom) became the first drug approved in the US for MASH. Five leading North American MASLD patient advocates join the Surfers to discuss their feelings about this approval along with the opportunities and challenges that lie ahead.
The conversation on Rezdiffra, the first MASH drug, wraps up with the panelists answering a inviation to discuss any other issues of interest that had not arisen in the conversation.
This conversation focuses on what panelists believe to be the major lessons the BioPharma industry should take from Madrigal’s success in bring Rezdiffra to launch.
As panelists ponder practical issues about when and to whom to prescribe Rezdiffra, they consider the benefits and shortcomings of existing NITs.
Last Thursday, FDA approved Rezdiffra, the first MASH drug! A global panel of key opinion leaders joins the Surfers to share excitement and discuss the implications of this landmark event.
This final conversation focuses on semaglutide and some of the dual- and triple-increting agonists and then reviews high points of the entire episode.
In the podcast episode, panelists delve into the shifting landscape of diagnosing and treating F2/3 MASH patients using non-invasive tests (NITs). They discuss challenges with current diagnostic tools, upcoming blood-based tests, and the potential impact of new drugs like resmetirom and GLP-1s on treatment strategies, aiming to optimize changes in the industry once a drug is approved.
This conversation reviews several other topics related to the new MASLD nomenclature: impact on NITs and ICD codes, future vision for MASH, and general satisfaction with the process to date.
